8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003453-28-ES (EUCTR) | 28/03/2022 | 30/12/2021 | Phase IIb study assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. | Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. | Huntington’s Disease with choreic movements. MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Calvan (bevantolol hydrochloride) Product Name: SOM3355 (bevantolol hydrochloride) Product Code: SOM3355 INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE Trade Name: Calvan (bevantolol hydrochloride) Product Name: SOM3355 (bevantolol hydrochloride) Product Code: SOM3355 INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE | SOM Innovation Biotech SA (SOM Biotech) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 129 | Phase 2 | France;Poland;Spain;Germany;United Kingdom;Switzerland;Italy |